Disease Overview：Mantle Cell Lymphoma（MCL）
Mantle cell lymphoma (MCL) is a rare, aggressive subtype of B-cell non-Hodgkin lymphoma characterized by the overexpression of cyclin D1 due to the t(11;14)(q13;q32) chromosomal translocation. It typically presents in older adults, with median age at diagnosis around 65 years, and often involves lymph nodes, bone marrow, gastrointestinal tract, and extranodal sites. Clinical course varies but frequently follows an initial response to therapy followed by relapse; prognosis remains challenging, with median overall survival ranging from 5–7 years despite advances in chemoimmunotherapy, BTK inhibitors (e.g., ibrutinib, zanubrutinib), and emerging CAR-T cell therapies. Accurate diagnosis requires integrated assessment—including flow cytometry, immunohistochemistry (CD5+, CD20+, cyclin D1+), and molecular testing—to distinguish MCL from morphologically similar lymphomas.
China offers compelling advantages for MCL management: leading oncology centers—such as Peking University Cancer Hospital and Fudan University Shanghai Cancer Center—house NMPA-approved BTK inhibitors and FDA-authorized CAR-T platforms (e.g., relmacabtagene autoleucel), supported by multidisciplinary tumor boards and real-world evidence from >2,000 treated cases. Treatment protocols align with NCCN and ESMO guidelines, yet costs are typically 40–60% lower than in the US or Western Europe without compromising quality. As a dedicated medical tourism agency, we facilitate seamless international care—vetting accredited hospitals, coordinating diagnostic workups and treatment timelines, providing transparent all-inclusive pricing (covering consultations, therapy, accommodation, and interpreter services), and offering end-to-end support from visa assistance to post-treatment follow-up coordination.
Mantle Cell Lymphoma: treatment in China helps patients compare specialist hospitals, initial assessment steps and estimated costs that may vary by city, institution and clinical condition.
Medical Treatment Guide
Treatment Options & Itemized Cost Breakdown: Mantle Cell Lymphoma (MCL)
Non-Surgical / Systemic Therapy Options
*Eligibility*: Newly diagnosed, relapsed/refractory, or transplant-ineligible patients; confirmed by biopsy, flow cytometry (CD5+, CD20+, cyclin D1+), and FISH for *CCND1* translocation.
- •First-Line Chemoimmunotherapy (e.g., VR-CAP or BR)
- Rituximab + Bendamustine (BR): ¥32,000–¥41,000/cycle × 6 cycles ($4,500–$5,700) - *Supportive labs per cycle*: CBC, LDH, renal/hepatic panel, β2-microglobulin — ¥420 ($60) - *Baseline diagnostics*: Bone marrow biopsy + aspirate, PET-CT, CT neck/chest/abdomen/pelvis — ¥12,800 ($1,800)
- •Targeted Therapy (BTK Inhibitors)
- Acalabrutinib: ¥24,500/month ($3,400/month) - *Monitoring labs (q3mo)*: CBC, LFTs, coagulation panel — ¥380 ($55)
- •Maintenance Rituximab
Surgical / Procedural Options
*Surgery is not curative but supports diagnosis/staging or manages complications.*
- •Diagnostic Lymph Node Biopsy (excisional)
- Procedure fee (Grade 3A hospital): ¥2,100–¥3,400 ($300–$480) - Pre-op workup (ECG, chest X-ray, PT/INR, platelets): ¥1,350 ($190)
- •Therapeutic Splenectomy (rare, for symptomatic hypersplenism or refractory cytopenias)
- Laparoscopic procedure: ¥18,600–¥24,900 ($2,600–$3,500) - Pre-op: Enhanced CT abdomen, viral serologies, pneumococcal vaccination — ¥2,900 ($410)
Special/Complex Condition Management
- •Autologous Stem Cell Transplant (ASCT)
- Total cost (mobilization, collection, conditioning [BEAM], infusion, 30-day monitoring): ¥142,000–¥178,000 ($19,900–$25,000)
- •CAR-T Therapy (e.g., Brexucabtagene autoleucel)
- Total (leukapheresis, manufacturing, infusion, 30-day toxicity management): ¥398,000–¥442,000 ($55,800–$62,000)
Quick Selection Guide
- •<60 years, fit, no comorbidities: BR → ASCT → Rituximab maintenance ($22,000–$32,000 total)
- •60–75 years, moderate comorbidities (e.g., hypertension, mild CKD): VR-CAP → maintenance ($28,000–$36,000)
- •>75 years or frail: BTK inhibitor monotherapy ($2,700–$3,400/month; median duration 24–36 mo)
- •Relapsed/refractory after BTKi + chemo: CAR-T if eligible ($55,800–$62,000 one-time)
- •Budget-constrained (<$15,000): BR regimen + supportive care ($4,500–$5,700/cycle × 6 = $27,000–$34,200; consider provincial insurance coverage reducing out-of-pocket to ~$6,000–$9,000)
Pricing & Service Differences: International / VIP Dept vs. Regular Clinic
International Medical Services (IMS / VIP Departments) at Grade-3A public hospitals and private international clinics operate under self-regulated VIP fee schedules. Fees are higher than standard public clinics (which are subsidized solely for domestic citizens and do not accept overseas insurances). In exchange, international patients receive 6 exclusive medical privileges:
Recommended Hospitals
Explore selected Grade 3A public hospitals in China with rich clinical experience for this condition:
🌴 Recommended Mantle Cell Lymphoma Medical Vacation Packages
Curated transparent all-inclusive packages combining Mantle Cell Lymphoma treatment with China top medical destinations:
